SAN DIEGO, June  12, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating TransMedics Group, Inc. (NASDAQ:TMDX) on behalf of investors who suffered losses and whether those losses may be recoverable under

TMDX

Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments

Securities Investigation of TransMedics may weigh on TMDX stock

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, June  12, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating TransMedics Group, Inc. (NASDAQ:TMDX) on behalf of investors who suffered losses and whether those losses may be recoverable under</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Johnson Fistel has launched a securities-law investigation into TransMedics (TMDX) after the May 5, 2026 quarterly results, triggering near-term volatility. The results showed revenue up 21% to $173.9m but margins declined and 2026 adjusted operating margin guidance was below 2025 levels. The investigation&#039;s outcome could affect sentiment, cost exposure, and potential volatility in TMDX shares.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Johnson Fistel launches investigation of TransMedics (TMDX) after Q1 results.</li><li>Q1 2026 revenue $173.9m, +21% YoY; gross margin 58%, operating margin 7.6%.</li><li>Adjusted operating margin for 2026 expected to be below 2025 levels.</li><li>Stock declined sharply after disclosures; ongoing growth investments cited.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>TransMedics Group, Inc. (TMDX)</strong>: Subject of ongoing securities-law investigation; Q1 margins showed compression despite growth.</li><li><strong>Johnson Fistel, PLLP (N/A)</strong>: Securities-fraud focused law firm leading the investigation and investor outreach.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Legal and investor-rights inquiry category; the news centers on an external securities-law investigation linked to a life-sciences tech company, influencing sentiment and volatility more than immediate fundamentals.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>TransMedics stock fell sharply after the disclosure of the investigation.</li><li>Outcome of the investigation could drive further near-term volatility in TMDX shares.</li><li>Management noted continued investments raising near-term profitability concerns.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Q1 2026 revenue approximately $173.9 million, up 21% YoY.</li><li>Gross margin 58% vs 61% prior year.</li><li>Operating margin 7.6% vs 19.1% prior year.</li><li>Adjusted operating margin 10.4% vs 20.7% prior year.</li><li>Operating expenses about $87.9 million vs $60.8 million in Q1 2025.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bearish near-term risk for TMDX on legal scrutiny; monitor updates over the next 2–6 weeks.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN DIEGO, June  12, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TMDX">TMDX</a>) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.</p>  <p><strong>TransMedics Investors: Contact Johnson Fistel</strong><br></br>If you purchased TransMedics securities and suffered losses on your investment, you are encouraged to <a href="https://www.globenewswire.com/Tracker?data=wm-l-y2XtRl7PWmR5ZNzA9tmmxH1o3Qle77sJdn_vEIBcnKvo9rZujvB6Z3GbKyPqTCfb54fmBH4YeLn1WrahI8_39eKqfJwDle_RwlZM165hcuRCkVDyX4UOzXloFduueaVIpsM_C_uP7EBTIPv0sgzikBqo00kWJppecq_fiY=" rel="nofollow" target="_blank">click here to join the investigation</a>.</p>  <p>For more information, contact Jim Baker at <a href="https://www.globenewswire.com/Tracker?data=04tQh4Bea9jVgOWUEbgeYV3KFDb3TFrPbpMbGAqku0wSbaVKWDb_bErDHGMumhHIEkvUlgIxIOJ5S60VkCJTdILTXVp-GSVMylMAZG39zng=" rel="nofollow" target="_blank">jimb@johnsonfistel.com</a> or (619) 814-4471.</p>  <p>There is no cost or obligation to you.</p>  <p><strong>Background of the Investigation</strong><br></br>TransMedics is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. The Company operates the Organ Care System, or OCS, and the National OCS Program, or NOP.</p>  <p>On May 5, 2026, after the market closed, TransMedics reported its first quarter 2026 financial results. The Company reported total revenue of approximately $173.9 million, representing a 21% increase compared to the first quarter of 2025.</p>  <p>The Company reported gross margin of 58%, compared to 61% in the prior-year period. Operating margin declined to 7.6%, compared to 19.1% in the first quarter of 2025, and adjusted operating margin declined to 10.4%, compared to 20.7% in the prior-year period.</p>  <p>TransMedics stated that gross margin was impacted primarily by investments to support growth and scale, together with higher supply chain and operating costs compared to the prior year. The Company also disclosed that operating expenses increased to approximately $87.9 million, compared to $60.8 million in the first quarter of 2025, driven primarily by increased research and development investment and investment throughout the organization to support the Company's growth.</p>  <p>During the Company's May 5, 2026 earnings call, management discussed continued investments in clinical programs, technology, international expansion initiatives, and the Company's NOP aviation and logistics network. TransMedics also advised investors that adjusted operating margin for 2026 was expected to be below 2025 levels despite continued revenue growth expectations.</p>  <p>Following these disclosures, TransMedics' stock price declined sharply.</p>  <p>In light of these recent disclosures, Johnson Fistel is investigating whether TransMedics complied with federal securities laws. If you suffered losses, or are a long-term holder of TransMedics stock, contact Johnson Fistel.</p>  <p><strong>About Johnson Fistel, PLLP &#x7C; Securities Fraud &amp; Investor Rights</strong><br></br>Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder litigation involving securities fraud, breaches of fiduciary duties, and other violations of state and federal law.</p>  <p>Johnson Fistel has been recognized as one of the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. In 2024, the firm recovered approximately $90,725,000 for investors.</p>  <p>Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. This press release may be considered a promotional communication. The attorney responsible for this communication is Frank J. Johnson.</p>  <p><strong>Contact</strong><br></br>Johnson Fistel, PLLP<br></br>501 W. Broadway, Suite 800<br></br>San Diego, CA 92101<br></br>James Baker, Investor Relations – or – Frank J. Johnson, Esq.<br></br>(619) 814-4471<br></br><a href="https://www.globenewswire.com/Tracker?data=04tQh4Bea9jVgOWUEbgeYV3KFDb3TFrPbpMbGAqku0xVCxrCqwp6V_-mS8sKCJhsLjgcejJOoKStC8nCmtAqNVwFd9XV9IohVmEzjcXhECc=" rel="nofollow" target="_blank">jimb@johnsonfistel.com</a> &#x7C; <a href="https://www.globenewswire.com/Tracker?data=OhLSu7NFLR43nkmIUQxijD942rJ2i4ILBNsWF_-GFqAxJ8f7Vrkhr_0bTnDhT3jPgk8w_nqM8Mz_I8gIB5KJ-E6r7kjMkjprzGKlylRZ1Q3JpS3ZDDNXQ2k9Gtk1z_pq" rel="nofollow" target="_blank">fjohnson@johnsonfistel.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc0NjA5OCM3NjU5MDQ1IzIxODE3ODk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ODU0MDJjNDgtYmJhZi00MTk3LTlkNGQtNTUyMTRkZDA3ZjVkLTExOTMzNTgtMjAyNi0wNi0xMi1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

Johnson Fistel has launched a securities-law investigation into TransMedics (TMDX) after the May 5, 2026 quarterly results, triggering near-term volatility. The results showed revenue up 21% to $173.9m but margins declined and 2026 adjusted operating margin guidance was below 2025 levels. The investigation's outcome could affect sentiment, cost exposure, and potential volatility in TMDX shares.

Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News